journal article·2023-05-26

Silica Coated Upconversion Nanoplatform for Ag-Based Chemo-/Photodynamic Therapy against Drug-Resistant Bacteria

Yuxian Su, Yingyan Mao, Shen Wu, Li Liu, Shipeng Wen

ACS Applied Nano Materials· Volume 6· Issue 10
Publisher page

Abstract

Near-infrared (NIR) driven photodynamic therapy based on upconversion luminescent nanoparticles (UCNPs) is promising for fighting drug-resistant bacteria infections in deep tissues due to its good noninvasive, nonspecific, and non-drug-resistant properties, but is greatly limited by its low efficacy. Herein, honeycomb-silica-coated upconversion nanoparticles (UCNP@mSiO 2 ) with a size of less than 100 nm were successfully prepared by a typical silica sol–gel reaction assisted with an expanding agent ( p -xylene). The honeycomb silica shell has large pores with an average diameter of about 10 nm and large pore volume of 0.82 cm 3 /g and exhibits a MC540 loading as high as 9% in weight. The UCNP nanoparticle core can effectively capture NIR photons and activate the merocyanine 540 photosensitizer (MC540), generating reactive oxygen species to kill the drug-resistant bacteria of deep tissues. To avoid the drug prerelease, Ag nanoparticles in diameter close to that of the silica hole were covalently grafted onto the aminated UCNP@MC540@mSiO 2 (UMS-NH 2 ) nanoparticle. The Ag-decorated UMS-NH 2 nanoparticles (UMSAg) showed synergistic antibacterial effects of Ag chemotherapy and photodynamic therapy and are more stable than undecorated UMS nanoparticles in an aqueous medium. The UMSAg with unreacted amino groups enhanced the binding of Ag to the bacterial membrane, effectively exerting the antibacterial effect of Ag + and ROS. In in vitro antibacterial experiments, the killing rates of the UMSAg composite (150 μg/mL) against drug-resistant Staphylococcus aureus and drug-resistant Pseudomonas aeruginosa under NIR irradiation were 100% and 99.6%, respectively. In addition, the antibacterial activity of the UMSAg group was significantly higher than that of the sole Ag nanoparticles without irradiation. This work provides good insight for the design of efficient antibacterial agents and has a potential application for the bacterial infection of deep tissues.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence Properties of Advanced Materials · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Organic−Inorganic Composites, Beijing University of Chemical Technology, Beijing 100029, China

Beijing Engineering Research Center of Advanced Elastomers, Beijing University of Chemical Technology, Beijing 100029, China

Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing 100730, China

Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing Tongren Hospital, Beijing 100730, China

Funding

National Natural Science Foundation of China · Beijing Science and Technology Planning Project

References (35)

Show source-provided references
1. 10.1021/acsami.9b1009610.1021/acsami.9b10096 ↗
2. 10.1016/j.actbio.2022.02.01310.1016/j.actbio.2022.02.013 ↗
3. 10.1039/D0BM02057E10.1039/D0BM02057E ↗
4. 10.1016/j.medcle.2019.11.00510.1016/j.medcle.2019.11.005 ↗
5. 10.1016/j.ejmech.2019.04.05710.1016/j.ejmech.2019.04.057 ↗
6. 10.1097/MCC.000000000000053410.1097/MCC.0000000000000534 ↗
7. 10.1016/j.phrs.2020.10527610.1016/j.phrs.2020.105276 ↗
8. 10.1002/anie.20191670410.1002/anie.201916704 ↗
9. 10.1021/acsnano.0c0008210.1021/acsnano.0c00082 ↗
10. 10.1016/j.cej.2018.09.07710.1016/j.cej.2018.09.077 ↗
11. 10.1021/acsami.9b0703710.1021/acsami.9b07037 ↗
12. 10.1016/j.nantod.2018.02.01010.1016/j.nantod.2018.02.010 ↗
13. 10.1002/adhm.20190060810.1002/adhm.201900608 ↗
14. 10.1016/j.actbio.2021.08.03710.1016/j.actbio.2021.08.037 ↗
15. 10.1039/C8NR01967C10.1039/C8NR01967C ↗
16. 10.1016/j.ccr.2018.11.01410.1016/j.ccr.2018.11.014 ↗
17. 10.1039/D1QI01569A10.1039/D1QI01569A ↗
18. 10.1002/adma.20150328010.1002/adma.201503280 ↗
19. 10.1016/j.msec.2020.11138210.1016/j.msec.2020.111382 ↗
20. 10.1021/acsanm.0c0092510.1021/acsanm.0c00925 ↗
21. 10.1039/C9TB00440H10.1039/C9TB00440H ↗
22. 10.1016/j.cis.2020.10217810.1016/j.cis.2020.102178 ↗
23. 10.1016/j.jhazmat.2022.12843610.1016/j.jhazmat.2022.128436 ↗
24. 10.1002/adhm.20170150310.1002/adhm.201701503 ↗
25. 10.1016/j.actbio.2017.01.02710.1016/j.actbio.2017.01.027 ↗
26. 10.1016/j.cej.2018.04.09210.1016/j.cej.2018.04.092 ↗
27. 10.1016/j.cej.2019.03.27310.1016/j.cej.2019.03.273 ↗
28. 10.1021/acsanm.1c0309110.1021/acsanm.1c03091 ↗
29. 10.1002/adfm.20110196010.1002/adfm.201101960 ↗
30. 10.1016/j.jcis.2017.09.04910.1016/j.jcis.2017.09.049 ↗
31. 10.1021/acsami.5b0093710.1021/acsami.5b00937 ↗
32. 10.1007/s10971-016-4163-410.1007/s10971-016-4163-4 ↗
33. 10.1021/acsami.9b1646110.1021/acsami.9b16461 ↗
34. 10.1039/C7NR04877G10.1039/C7NR04877G ↗
35. 10.1021/acsnano.9b0538610.1021/acsnano.9b05386 ↗